ZEVTERA (ceftobiprole medocaril)
Community-acquired bacterial pneumonia (CABP) and Staphylococcus aureus bacteremia (SAB)
MarketedApproved
Key Facts
Indication
Community-acquired bacterial pneumonia (CABP) and Staphylococcus aureus bacteremia (SAB)
Phase
Marketed
Status
Approved
About Innoviva Specialty Therapeutics
Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc. (NASDAQ: INVA), is a mission-driven biotech focused on addressing high unmet medical needs in critical care and infectious diseases through a strategic asset-centric model. The company has built a portfolio of five marketed products and a late-stage pipeline via targeted acquisitions and in-licensing, followed by expert development and commercialization. Its commitment to combating antimicrobial resistance was externally validated by a top-tier 80% performance rating in the 2026 Access to Medicine Foundation's AMR Benchmark Report.
View full company profile